NCT05775159 2026-04-17Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerAstraZenecaPhase 2 Recruiting294 enrolled
NCT07530445 2026-04-15Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerSun Yat-sen UniversityPhase 2 Recruiting40 enrolled